JERUSALEM, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today, in conjunction with the release of the Sanofi-Aventis group’s financial results, that global in-market sales of Copaxone® in the third quarter of 2006 grew by 15% as compared to the third quarter of 2005 and reached a record of $354 million.
